Jean Luc Raoul
Overview
Explore the profile of Jean Luc Raoul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopresti A, Malergue F, Bertucci F, Liberatoscioli M, Garnier S, DaCosta Q, et al.
JCI Insight
. 2019 Jun;
5.
PMID: 31194699
Circulating Tumor Cells (CTCs) represent an easy, repeatable and representative access to information regarding solid tumors. However, their detection remains difficult because of their paucity, their short half-life, and the...
2.
Pesenti C, Bories E, Caillol F, Ratone J, Godat S, Monges G, et al.
Endosc Ultrasound
. 2018 Sep;
8(1):43-49.
PMID: 30264741
Background And Objectives: Subepithelial lesions (SELs) of the upper part of the digestive tract are rare, and it can be difficult to characterize them. Recently, contrast-enhanced endosonography (EUS) and elastometry...
3.
Adhoute X, Penaranda G, Raoul J, Sellier F, Castellani P, Oules V, et al.
Eur J Gastroenterol Hepatol
. 2018 Feb;
30(4):368-375.
PMID: 29384796
Background: Direct-acting antivirals (DAAs) therapy against hepatitis C viral (HCV) infection has markedly improved the sustained viral response. However, recent studies have suggested an unsuspected high rate of hepatocellular carcinoma...
4.
Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz H, Raoul J, et al.
Br J Cancer
. 2017 Nov;
118(2):181-188.
PMID: 29161241
Background: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease...
5.
Adhoute X, Penaranda G, Raoul J, Bourliere M
Liver Int
. 2017 Sep;
38(1):187.
PMID: 28952186
No abstract available.
6.
Gilabert M, Raoul J, Rousseau F
J Geriatr Oncol
. 2017 Sep;
8(6):407-412.
PMID: 28888554
Pancreatic adenocarcinoma is one of the most fatal cancers that frequently affects older patients. Limited data suggest that older patients are as likely to benefit from surgery, radiation, and chemotherapy...
7.
Adhoute X, Penaranda G, Raoul J, Edeline J, Blanc J, Pol B, et al.
World J Gastroenterol
. 2017 May;
23(14):2545-2555.
PMID: 28465639
Aim: To compare the performances of the Barcelona clinic liver cancer (BCLC) nomogram and others systems (BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma (HCC) French...
8.
Gilabert M, Chanez B, Rho Y, Giovanini M, Turrini O, Batist G, et al.
Medicine (Baltimore)
. 2017 Apr;
96(16):e6544.
PMID: 28422841
To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen.Patients with locally-advanced or metastatic pancreatic adenocarcinoma from French and Canadian centers, who were treated with the first-line...
9.
Boisdron-Celle M, Metges J, Capitain O, Adenis A, Raoul J, Lecomte T, et al.
Semin Oncol
. 2017 Apr;
44(1):24-33.
PMID: 28395759
We conducted a multicenter proof of concept phase II trial in patients with advanced colorectal cancer receiving FOLFIRI-cetuximab regimens to explore individual drug tailoring using pharmacogenetics and pharmacokinetics (PK) monitoring....
10.
Adhoute X, Penaranda G, Raoul J, Bollon E, Pol B, Letreut Y, et al.
Eur J Gastroenterol Hepatol
. 2017 Feb;
29(6):706-715.
PMID: 28195873
Background And Aims: Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The...